Get started

Healthcare

Sanofi S.A. (SAN.pa) bearish scenario:The technical figure Channel Up can be found in the daily chart in the French company Sanofi S.A. (SAN.pa). Sanofi S.A. is a French multinational pharmaceutical and healthcare company. Sanofi engages in the research and development, manufacturing and marketing of pharmacological products, principally in the prescription market, but the firm also develops over-the-counter medications. The corporation covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines (it is the world's largest producer of the last through its subsidiary Sanofi Pasteur). The Channel Up broke through the support line on 24/01/2023. If the price holds below this level, you can have a possible bearish price movement with a forecast for the next 26 days towards 86.54 EUR. According to experts, your stop-loss order should be placed at 92.90 EUR if you decide to enter this position. French drugmaker Sanofi SA plans to launch a drug for rare bleeding disorder hemophilia A this year, Chief Executive Officer Paul Hudson told CNBC in an interview last week. The U.S. Food and Drug Administration last year accepted the marketing application for the therapy, which is being developed in collaboration with Swedish drugmaker Sobi, and is expected to decide on an approval status by Feb. 28. Hemophilia A is an inherited bleeding disorder in which the blood does not clot normally. About 400 babies are born with this condition every year, although the exact number of people affected is not known, according to government data. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
EURONEXT:SANShort
by legacyFXofficial
3M Co. (MMM) bearish scenario:The technical figure Triangle can be found in the daily chart of the US company 3M Co. (MMM). 3M (originally the Minnesota Mining and Manufacturing Company) is an American multinational conglomerate operating in the fields of industry, worker safety, U.S. health care, and consumer goods. The company produces over 60,000 products under several brands, including adhesives, abrasives, laminates, passive fire protection, personal protective equipment, window films, paint protection films, dental and orthodontic products, electrical and electronic connecting and insulating materials, medical products, car-care products, electronic circuits, healthcare software and optical films. The Triangle broke through the support line on 20/01/2023. If the price holds below this level, you can have a possible bearish price movement with a forecast for the next 22 days towards 108.57 USD. Your stop-loss order, according to experts, should be placed at 129.63 USD if you decide to enter this position. Wall Street will be looking for positivity from 3M as it approaches its next earnings report date. This is expected to be January 24, 2023. On that day, 3M is projected to report earnings of $2.34 per share, which would represent year-over-year growth of 1.3%. Meanwhile, our latest consensus estimate is calling for revenue of $8.04 billion, down 6.69% from the prior-year quarter. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
NYSE:MMMShort
by legacyFXofficial
2
CVS | FINALLY Time to Enter | LONGCVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. Its Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, plans offered on public health insurance and private health insurance exchanges, other sponsors of health benefit plans, and individuals. This segment operates retail specialty pharmacy stores; and specialty mail-order, mail-order dispensing, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. The company's Retail/LTC segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products; and provides health care services through its MinuteClinic walk-in medical clinics. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. As of December 31, 2021, it operated approximately 9,900 retail locations and 1,200 MinuteClinic locations, as well as online retail pharmacy websites, LTC pharmacies, and onsite pharmacies. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.
NYSE:CVSLong
by DivergenceSeeker
2
GMVD | A Low Float Monster | Oversold G Medical Innovations Holdings Ltd, together with its subsidiaries, an early commercial stage healthcare company, engages in the development of next generation mobile health and telemedicine solutions in the United States, China, and Israel. The company's products include Prizma, a plug-and-play medical device that measures vital signs with electronic medical records functionality and clinical grade reporting standards; and Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiogram data continuously for up to 14 days. It also develops Wireless Vital Signs Monitoring System, a solution that provides continuous real time monitoring of vital signs and biometrics. In addition, it offers monitoring services, including independent diagnostic testing facility monitoring and private monitoring services. The company was incorporated in 2014 and is based in Rehovot, Israel.
GLong
by DivergenceSeeker
2
UNITED HEALTH Buy Opportunity for this quarterThe UnitedHealth Group (UNH) hit the Resistance Zone following our last (November 18) signal but as it failed to break through its top, it got rejected: By doing so, the price even broke below the Higher Lows trend-line and the Bullish Megaphone pattern, that were in effect since February 2021. This potentially signals a deceleration on its enormous and sustainable rise but not necessarily that it turns bearish. In order to do so, it needs a closing below the 1W MA100 (red trend-line). Right now with the price on the 0.382 Fibonacci level and the 1D RSI oversold at 30.000, it is on the very same spot it was on the June 17 2022 Low. See between the two fractals, the successive hits on the 1D MA200 (orange trend-line) and 1D MA50 (blue trend-line). As a result, we consider this a buy opportunity back to the bottom (551.00) of the Resistance Zone. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support me, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- You may also TELL ME 🙋‍♀️🙋‍♂️ in the comments section which symbol you want me to analyze next and on which time-frame. The one with the most posts will be published tomorrow! 👏🎁 ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:UNHLong
by TradingShot
2
Early entry in small cap health services, $MEDPSince late 2021 NASDAQ:MEDP is being forming a head & shoulders base with pivot buy above $230. This is the beahvior of a potential leader. It shows when comparing it against the AMEX:IWO as is still in a downtrend. The play for me would be to buy 1/2 or 1/3 of a position just above yesterday's high with a STOP-LOSS below $196. And then add at the $230 pivot. Medpace Holdings is ranked #1 in its industry by IBD. I recomend to also check NYSE:VPG which is also setting up. Its being hard for small caps to get demand as the indices are still in downtrends making the sentiment stay bearish. But as JC Parets always likes to remember, "is a market of stocks, not a stock market".
NASDAQ:MEDPLong
by dpuleo19
VIRX | I Like These Setups | OversoldViracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
NASDAQ:VIRXLong
by DivergenceSeeker
1
Baxter (BAX) bullish scenario:The technical figure Pennant can be found in the daily chart in the US company Baxter International Inc. (BAX). Baxter International Inc. is an American multinational healthcare company. The company primarily focuses on products to treat kidney disease, and other chronic and acute medical conditions. The company had 2017 sales of $10.6 billion, across two businesses: BioScience and Medical Products. Baxter's BioScience business produces recombinant and blood plasma proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies and other chronic and acute blood-related conditions; products for regenerative medicine, and vaccines. Baxter's Medical Products business produces intravenous products and other products used in the delivery of fluids and drugs to patients; inhalational anaesthetics; contract manufacturing services; and products to treat end-stage kidney disease, or irreversible kidney failure, including products for peritoneal dialysis and hemodialysis. The Pennant broke through the resistance line on 28/12/2022. If the price holds above this level, you can have a possible bullish price movement with a forecast for the next 6 days towards 53.63 USD. Your stop-loss order, according to experts, should be placed at 49.17 USD if you decide to enter this position. Baxter International Inc. has announced that it will pay a dividend of $0.29 per share on the 3rd of January. This means the dividend yield will be fairly typical at 2.1%. Analysts expect a massive rise in earnings per share in the next year. If the dividend extends its recent trend, estimates say the dividend could reach 17%, which we would be comfortable to see continuing. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
NYSE:BAXLong
by legacyFXofficial
ATNF | Is My Math Off? | LONG1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
NASDAQ:ATNFLong
by DivergenceSeeker
2
RDHL | Good Entry Point | LONGRedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
NASDAQ:RDHLLong
by DivergenceSeeker
2
KERN | Huge Institutional Ownership | LONGAkerna Corp. provides enterprise software solutions that enable regulatory compliance and inventory management in United States and Canada. The company offers MJ Platform for the cannabis, hemp, and CBD industry; and Leaf Data Systems, a government regulatory software. It also provides consulting services to cannabis industry; business intelligence, data analytics and other software related services; and Last Call Analytics, a tool for alcohol brands to analyze their retail sales analytics. In addition, the company operates seed-to-sale platform that offers tracking, reporting, and compliance tools to cannabis cultivators, processors, sellers, and clinics. Further, it provides cannabis cultivation management and compliance software; and cannabis tracking technology that offers seed-to-sale-to-self data. Akerna Corp. was founded in 2010 and is headquartered in Denver, Colorado.
KLong
by DivergenceSeeker
Two healthcare leaders, which one is best to own? NASDAQ:PODD & NASDAQ:DXCM are leading the sectors recovery. Both are in the Medical Products Industry for diabetes. Insulent (PODD) normally outperforms DexCom (DXCM) during and after a correction. Then, when they are in sustained uptrends, DXCM outperforms. For the recent correction, PODD has a -45% deep base while DXCM has a -58%. PODD bottmed 4 weeks before DXCM, but DXCM has rallied +74% and PODD +65% since. So, it really depends on your strategy. If you are looking for aplha then NASDAQ:DXCM is the stock for you but, if you prefer low beta then NASDAQ:PODD is better. Remember that aplha plays in both ways! Which are you trading? I'll trade the first that makes a new high.
NASDAQ:PODDLong
by dpuleo19
NKTX | Oversold Healthcare Play | LONGNkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
NASDAQ:NKTXLong
by DivergenceSeeker
SNDA | Great Entry Point | LONGSonida Senior Living, Inc. develops, owns, operates, and manages senior housing communities in the United States. The company provides independent living services, which include daily meals, transportation, social and recreational activities, laundry, housekeeping, and 24-hour staffing; and access to health screenings, periodic special services, and dietary and similar programs, as well as exercise and fitness classes. It also offers assisted living services consist of personal care services, such as assistance with activities of daily living, including ambulation, bathing, dressing, eating, grooming, personal hygiene, and monitoring or assistance with medications; support services, such as meals, assistance with social and recreational activities, laundry, general housekeeping, maintenance, and transportation services; and supplemental services, which include extra transportation, personal maintenance, and extra laundry services, as well as special care services for residents with various forms of dementia. In addition, the company provides memory care services; and home care services through third-party providers. As of December 31, 2021, it operated 75 senior housing communities in 18 states with an aggregate capacity of approximately 9,500 residents, including 60 senior housing communities. The company was formerly known as Capital Senior Living Corporation and changed its name to Sonida Senior Living, Inc. in November 2021. Sonida Senior Living, Inc. was founded in 1990 and is based in Addison, Texas.
NYSE:SNDALong
by DivergenceSeeker
JOHNSON & JOHNSON Can reach $190 by FebruaryJohnson & Johnson (JNJ) has been trading within a long-term Bullish Megaphone pattern since the January 26 2021 High. The pattern has been having very structured Higher Highs and Higher Lows. At the moment the stock is on a bullish leg, after rebounding exactly on the 1D MA50 (blue trend-line) on November 11 and is also above the 1D MA200 (orange trend-line). The 1W MACD is on a Bullish Cross and the 1W RSI rebounded off a Lower Lows (Double) Bottom formation. The exact same sequence was last seem early this year on January. After one last pull-back, the stock then rallied to the top (Higher Highs trend-line) of the Bullish Megaphone. The Higher Highs seem to be following the 1.236 - 1.5 - 1.786 Fibonacci sequence and so do the Lows (0.236 - 0.5 - 0.786). The 1.786 Fib extension is a little over $190.00 and that is our current long target on JNJ. ------------------------------------------------------------------------------- ** Please LIKE 👍, SUBSCRIBE ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support me, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- You may also TELL ME 🙋‍♀️🙋‍♂️ in the comments section which symbol you want me to analyze next and on which time-frame. The one with the most posts will be published tomorrow! 👏🎁 ------------------------------------------------------------------------------- 👇 👇 👇 👇 👇 👇 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:JNJLong
by TradingShot
2
UnitedHealthGroup Analysis 19.11.2022Welcome to the BasicTrading channel. My name is Philip and in todays analysis I quickly go over the situation which we currently have on UnitedHealth Group. I will analyse the asset both from a weekly and daily timeframe to show you the best possible trading opportunities. If you enjoyed this analysis, let me know in the comment section which asset I should analyse tomorrow. I will personally reply to every single comment. Dont forget to smash that rocket and I will see you tomorrow with a new analysis.
NYSE:UNH
by basictradingtv
3